Physician profile
Eric B Raimo
NPI 1568429389
$4,863.60
in general payments reported to CMS, 2019-2025
19 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $156 · 2021: $398 · 2022: $657 · 2023: $892 · 2024: $611 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,691 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,691.18 |
| Education | $142.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $820.71 | 2021-2025 | |
| Lundbeck LLC | $757.50 | 2019-2025 | Rexulti |
| Alkermes, INC. | $712.11 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $419.24 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $383.78 | 2019-2025 | Rexulti, Nuedexta |
| Axsome Therapeutics, INC. | $351.75 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $345.71 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $250.08 | 2019-2022 | |
| Allergan, INC. | $200.34 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $167.87 | 2019-2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $111.68 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $94.90 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $76.99 | 2024-2025 | Spravato |
| Shire North American Group INC | $45.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $39.92 | 2024-2025 | Austedo Xr, Austedo Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $28.91 | 2021 | |
| Bausch Health US, LLC | $24.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.81 | 2023 | Quviviq |
| Indivior INC. | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Raimo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.